Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.
Saved in:
| Title: | Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. |
|---|---|
| Authors: | Liu, Ying L.1,2 (AUTHOR) liuy3@mskcc.org, Mathews, Cara A.3 (AUTHOR), Simpkins, Fiona4 (AUTHOR), Cadoo, Karen A.1,5 (AUTHOR), Provencher, Diane6 (AUTHOR), McCormick, Colleen C.7,8 (AUTHOR), ElNaggar, Adam C.9 (AUTHOR), Altman, Alon D.10 (AUTHOR), Gilbert, Lucy11 (AUTHOR), Black, Destin12 (AUTHOR), Kabil, Nashwa13 (AUTHOR), Taylor, Rosie N.14 (AUTHOR), Barnicle, Alan14 (AUTHOR), Munley, Jiefen Y.15 (AUTHOR), Aghajanian, Carol1,2 (AUTHOR) |
| Source: | Cancer (0008543X). 1/15/2025, Vol. 131 Issue 2, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 0008543X |
|---|---|
| DOI: | 10.1002/cncr.35707 |
